Skip to Main Content


Skip Nav Destination

Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9

Cancer Res (2019) 79 (13_Supplement): 2257.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Salima Shebbo
  • Najat Binothman
  • Manar Darwaish
  • Hanan A. Niaz
  • Rwaa H. Abdulal
  • Jamilah Borjac
  • Anwar M. Hashem
  • Ahmad Bakur Mahmoud
Frontiers in Immunology (2024) 15
Close Modal

or Create an Account

Close Modal
Close Modal